Adjuvant hormonotherapy in breast cancer - is “the option zero” realistic?

Krzysztof Krzemieniecki, Marek Pawlicki

Full Text:

View PDF (polish)

Abstract

Adjuvant hormonal therapy increases disease free interval and overall survival, reduces risk of distant
metastases and second breast cancer in patients with hormone-sensitive early breast cancer.

Documented clinical advantage of aromatase inhibitors led to numerous trials on the use of this class of
agents in the adjuvant setting for postmenopausal women. Based on the results of these trials sufficient
data exist to consider sequential hormonotherapy, although there are still some not resolved elements of
this strategy. Primary adjuvant hormonotherapy with aromatase inhibitors seems to be limited to patients
in whom tamoxifen is contraindicated or not tolerated. Expert panels advise to be cautious and potential
guidelines modifications should be based on the final results of current studies with clarification of all
controversial issues.
At present, the results of several studies on the use of hormonal adjuvant therapy in premenopausal
women are available and they give some evidence to switch for hormonal therapy and gonadoliberin
analogues in the adjuvant setting. More data are necessary to establish optimal time framework for adjuvant
hormonotherapy.

Launching new drugs in adjuvant breast cancer therapy may require revision of current treatment guidance.
The future adjuvant therapy may be much more tailored based on individual genetic profile derived
from microarrays study.

Keywords

hormonosensitive breast cancer; adjuvant treatment; aromatase inhibitors; LHRH analogues

Refbacks

  • There are currently no refbacks.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl